Expertise in
2
conditions

Dr. Nikolaos A. Trikalinos

Hematology
Office
4921 Parkview Pl Fl 7, 
Saint Louis, MO 
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
Expertise in
2
conditions
Office
4921 Parkview Pl Fl 7, 
Saint Louis, MO 

Overview

Nikolaos Trikalinos is a Hematologist practicing medicine in Saint Louis, Missouri.

Dr. Trikalinos is highly rated in 2 conditions, according to our data. His clinical expertise encompasses Gastroesophageal Junction Cancer, Agranulocytosis, Acute Myeloid Leukemia (AML), Smoldering Multiple Myeloma, and Tissue Biopsy.

He is actively involved in clinical research, co-authoring 59 peer reviewed articles and participating in 20 clinical trials. Dr. Trikalinos is currently accepting new patients.

Specialties

Hematology

Licenses

Internal Medicine in MO

Hospital Affiliations

Barnes-Jewish St Peters Hospital
Barnes-Jewish West County Hospital
Barnes Jewish Hospital
Christian Hospital Northeast
Memorial Hospital

Languages Spoken

English
French
German
Greek
Portuguese
Spanish

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Cox Health
  • EPO
  • PPO
Essence Healthcare
  • INSURANCE PLAN
  • MEDICARE MAPD
Health Alliance
  • EPO
  • HMO
  • POS
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Home State Health
  • EPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Meridian Choice
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 12 Less Insurance Carriers -

Locations

Office
4921 Parkview Pl Fl 7, Saint Louis, MO 63110
Other Locations
Office
4500 Forest Park Ave Fl 5, Saint Louis, MO 63108

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

20 Clinical Trials

A Randomized Registry Trial of Adjuvant Mitotane vs. Mitotane With Cisplatin/Etoposide After Primary Surgical Resection of Localized Adrenocortical Carcinoma With High Risk of Recurrence (ADIUVO-2 Trial)
A Randomized Registry Trial of Adjuvant Mitotane vs. Mitotane With Cisplatin/Etoposide After Primary Surgical Resection of Localized Adrenocortical Carcinoma With High Risk of Recurrence (ADIUVO-2 Trial)
Enrollment Status: Recruiting
Publish Date: July 16, 2026
Intervention Type: Other, Drug
Study Drugs: Cisplatin, Etoposide, Mitotane
Study Phase: Phase 3
A Phase 2 Study of the PARP Inhibitor Olaparib (AZD2281) in IDH1 and IDH2 Mutant Advanced Solid Tumors
A Phase 2 Study of the PARP Inhibitor Olaparib (AZD2281) in IDH1 and IDH2 Mutant Advanced Solid Tumors
Enrollment Status: Active_not_recruiting
Publish Date: August 18, 2026
Intervention Type: Drug, Procedure
Study Drug: Olaparib
Study Phase: Phase 2
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET)
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET)
Enrollment Status: Active_not_recruiting
Publish Date: August 04, 2026
Intervention Type: Other, Procedure, Drug
Study Drug: Cabozantinib S-malate
Study Phase: Phase 3
A Phase 2 Study of XL184 (Cabozantinib) in Combination With Nivolumab and Ipilimumab for the Treatment of Poorly Differentiated Neuroendocrine Carcinomas
A Phase 2 Study of XL184 (Cabozantinib) in Combination With Nivolumab and Ipilimumab for the Treatment of Poorly Differentiated Neuroendocrine Carcinomas
Enrollment Status: Active_not_recruiting
Publish Date: July 31, 2026
Intervention Type: Biological, Drug
Study Drugs: Cabozantinib S-malate, Ipilimumab, Nivolumab
Study Phase: Phase 2
BAY 1895344 Plus Topoisomerase-1 (Top1) Inhibitors in Patients With Advanced Solid Tumors, Phase I Studies With Expansion Cohorts in Small Cell Lung Carcinoma (SCLC), Poorly Differentiated Neuroendocrine Carcinoma (PD-NEC) and Pancreatic Adenocarcinoma (PDA)
BAY 1895344 Plus Topoisomerase-1 (Top1) Inhibitors in Patients With Advanced Solid Tumors, Phase I Studies With Expansion Cohorts in Small Cell Lung Carcinoma (SCLC), Poorly Differentiated Neuroendocrine Carcinoma (PD-NEC) and Pancreatic Adenocarcinoma (PDA)
Enrollment Status: Active_not_recruiting
Publish Date: July 31, 2026
Intervention Type: Procedure, Drug
Study Drugs: Elimusertib, Irinotecan Hydrochloride, Topotecan Hydrochloride
Study Phase: Phase 1
A Phase 2 Study of AZD1775 in SETD2-Deficient Advanced Solid Tumor Malignancies
A Phase 2 Study of AZD1775 in SETD2-Deficient Advanced Solid Tumor Malignancies
Enrollment Status: Active_not_recruiting
Publish Date: July 31, 2026
Intervention Type: Drug
Study Drug: Adavosertib
Study Phase: Phase 2
Phase II Study of Stereotactic Body Radiotherapy and Focal Adhesion Kinase Inhibitor in Advanced Pancreas Adenocarcinoma
Phase II Study of Stereotactic Body Radiotherapy and Focal Adhesion Kinase Inhibitor in Advanced Pancreas Adenocarcinoma
Enrollment Status: Active_not_recruiting
Publish Date: May 08, 2026
Intervention Type: Procedure, Device, Drug
Study Drug: Defactinib
Study Phase: Phase 2
Non-Operative Management and Early Response Assessment in Rectal Cancer
Non-Operative Management and Early Response Assessment in Rectal Cancer
Enrollment Status: Completed
Publish Date: May 01, 2026
Intervention Type: Drug, Radiation
Study Phase: Not Applicable
Cabozantinib in High Grade Neuroendocrine Neoplasms
Cabozantinib in High Grade Neuroendocrine Neoplasms
Enrollment Status: Active_not_recruiting
Publish Date: April 06, 2026
Intervention Type: Procedure, Drug
Study Drug: Cabozantinib
Study Phase: Phase 2
A Phase I/II Study to Evaluate the Tolerability and Efficacy of BMS-813160 (CCR2/5 Inhibitor) With Nivolumab and Gemcitabine and Nab-paclitaxel in Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma (PDAC)
A Phase I/II Study to Evaluate the Tolerability and Efficacy of BMS-813160 (CCR2/5 Inhibitor) With Nivolumab and Gemcitabine and Nab-paclitaxel in Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma (PDAC)
Enrollment Status: Completed
Publish Date: July 29, 2025
Intervention Type: Drug, Procedure
Study Drugs: BMS-813160, Nivolumab, Gemcitabine, Nab-paclitaxel
Study Phase: Phase 1/Phase 2
View 9 Less Clinical Trials

59 Total Publications

Mapping Misconceptions in Neuroendocrine Tumor Nomenclature: A Scoping Review of National Database Studies and Clinical Implications.
Mapping Misconceptions in Neuroendocrine Tumor Nomenclature: A Scoping Review of National Database Studies and Clinical Implications.
Journal: Cancers
Published: June 25, 2026
Similar Doctors
Expertise in
28
conditions
Dr. Brad S. Kahl
Hematology
Expertise in
28
conditions
Dr. Brad S. Kahl
Hematology
Referral may be required

Washington University School Of Medicine

4921 Parkview Pl, 
Saint Louis, MO 
 (0.9 miles away)
314-747-1171
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Brad Kahl is a Hematologist practicing medicine in Saint Louis, Missouri. Dr. Kahl is highly rated in 28 conditions, according to our data. His clinical expertise encompasses Mantle Cell Lymphoma (MCL), Follicular Lymphoma, Non-Hodgkin Lymphoma, Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Kahl is currently accepting new patients.

Expertise in
24
conditions
Expertise in
24
conditions
Referral may be required

Washington University School Of Medicine

4921 Parkview Pl, 
Saint Louis, MO 
 (0.9 miles away)
314-747-1171
Experience:
17+ years
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Neha Mehta-Shah is a Hematologist practicing medicine in Saint Louis, Missouri. She has been practicing medicine for over 17 years. Dr. Mehta-Shah is highly rated in 24 conditions, according to our data. Her clinical expertise encompasses Peripheral T-Cell Lymphoma, T-Cell Lymphoma, Non-Hodgkin Lymphoma, Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Mehta-Shah is currently accepting new patients.

Expertise in
24
conditions
Expertise in
24
conditions
Referral may be required

Washington University

4500 Forest Park Ave, 
Saint Louis, MO 
 (1.5 miles away)
314-454-8304
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Geoffrey Uy is a Hematologist practicing medicine in Saint Louis, Missouri. Dr. Uy is highly rated in 24 conditions, according to our data. His clinical expertise encompasses Acute Myeloid Leukemia (AML), Leukemia, Myelodysplastic Syndrome (MDS), Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Uy is currently accepting new patients.

Frequently Asked Questions about Dr. Nikolaos A. Trikalinos

How do I make an appointment with Dr. Nikolaos A. Trikalinos?

You can book an appointment with Dr. Nikolaos A. Trikalinos by calling their office at 314-747-1171. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Nikolaos A. Trikalinos a top-rated expert for Gastroesophageal Junction Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Nikolaos A. Trikalinos is classified as an Advanced expert for Gastroesophageal Junction Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Nikolaos A. Trikalinos specialize in?

While Dr. Nikolaos A. Trikalinos is a Hematology, they have specific expertise in Gastroesophageal Junction Cancer, Agranulocytosis, and Acute Myeloid Leukemia (AML). MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Nikolaos A. Trikalinos participate in research or clinical trials?

Yes. Dr. Nikolaos A. Trikalinos has published 59 articles and abstracts on conditions like Gastroesophageal Junction Cancer. You can view a list of Dr. Nikolaos A. Trikalinos's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Nikolaos A. Trikalinos accept my insurance?

Dr. Nikolaos A. Trikalinos accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 314-747-1171 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Trikalinos's expertise for a condition
ConditionClose
      View All 29 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile